Hearing Improvement after Radiation Therapy for a Facial Nerve Schwannoma: Report of a Case and Review of Literature

IF 0.6 Q4 CLINICAL NEUROLOGY
Isabella L. Pecorari, Sayak R. Ghosh, H. Moskowitz, Vijay Agarwal
{"title":"Hearing Improvement after Radiation Therapy for a Facial Nerve Schwannoma: Report of a Case and Review of Literature","authors":"Isabella L. Pecorari, Sayak R. Ghosh, H. Moskowitz, Vijay Agarwal","doi":"10.1055/s-0044-1788071","DOIUrl":null,"url":null,"abstract":"\n Introduction While facial nerve schwannomas are considered benign, they can impart various significant clinical effects due to pressure on nearby cerebrovascular structures within the cerebellopontine angle (CPA). Although surgical resection and/or radiation therapy often provide definitive treatment of such tumors, posttreatment hearing loss is a common finding. In this report, we present the case of a patient with a facial nerve schwannoma successfully treated with radiotherapy with resultant hearing improvement, an extremely rare clinical finding.\n Case Presentation A 63-year-old woman presented with a 1-year history of progressively worsening hearing loss and tinnitus. Brain imaging demonstrated an enhancing lesion of the right CPA measuring 2.7 × 2.1 × 3.1 cm. Pretreatment audiometry evaluation revealed sensorineural hearing loss in the right ear with a pure-tone average (PTA) of 74 dB, speech threshold (ST) of 75 dB, and speech discrimination (SD) of 0%. The patient proceeded with attempted surgical resection, aborted due to significant facial nerve stimulation, and ultimately underwent radiation therapy (50.4 Gy, 28 fractions). At the 1-year follow-up visit, the patient reports subjective hearing loss resolution with PTA of 34 dB, 30 dB ST, and 88% SD on audiological evaluation.\n Conclusion Although radiation therapy for schwannomas within the CPA has historically been associated with hearing loss, fractionated stereotactic radiotherapy (FSRT) may provide improved clinical outcomes compared with high-dose radiosurgery. Given the effectiveness of this treatment modality and improved quality of life offered to patients over surgery, FSRT may be considered an initial management option for patients with facial nerve schwannomas.","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurological Surgery Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0044-1788071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction While facial nerve schwannomas are considered benign, they can impart various significant clinical effects due to pressure on nearby cerebrovascular structures within the cerebellopontine angle (CPA). Although surgical resection and/or radiation therapy often provide definitive treatment of such tumors, posttreatment hearing loss is a common finding. In this report, we present the case of a patient with a facial nerve schwannoma successfully treated with radiotherapy with resultant hearing improvement, an extremely rare clinical finding. Case Presentation A 63-year-old woman presented with a 1-year history of progressively worsening hearing loss and tinnitus. Brain imaging demonstrated an enhancing lesion of the right CPA measuring 2.7 × 2.1 × 3.1 cm. Pretreatment audiometry evaluation revealed sensorineural hearing loss in the right ear with a pure-tone average (PTA) of 74 dB, speech threshold (ST) of 75 dB, and speech discrimination (SD) of 0%. The patient proceeded with attempted surgical resection, aborted due to significant facial nerve stimulation, and ultimately underwent radiation therapy (50.4 Gy, 28 fractions). At the 1-year follow-up visit, the patient reports subjective hearing loss resolution with PTA of 34 dB, 30 dB ST, and 88% SD on audiological evaluation. Conclusion Although radiation therapy for schwannomas within the CPA has historically been associated with hearing loss, fractionated stereotactic radiotherapy (FSRT) may provide improved clinical outcomes compared with high-dose radiosurgery. Given the effectiveness of this treatment modality and improved quality of life offered to patients over surgery, FSRT may be considered an initial management option for patients with facial nerve schwannomas.
面神经室管膜瘤放射治疗后听力改善:病例报告与文献综述
导言:虽然面神经分裂瘤被认为是良性肿瘤,但由于会对小脑角(CPA)内附近的脑血管结构造成压力,因此会产生各种明显的临床影响。虽然手术切除和/或放射治疗通常能彻底治疗此类肿瘤,但治疗后听力下降是常见的症状。在本报告中,我们介绍了一例面神经分裂瘤患者的病例,该患者成功接受了放疗,并因此改善了听力,这在临床上极为罕见。病例介绍 一位 63 岁的女性患者因听力下降和耳鸣逐渐加重而就诊 1 年。脑部影像学检查显示,右侧 CPA 病灶增强,大小为 2.7 × 2.1 × 3.1 厘米。治疗前听力评估显示,患者右耳感音神经性听力损失,纯音平均值(PTA)为 74 dB,言语阈值(ST)为 75 dB,言语辨别率(SD)为 0%。患者尝试进行手术切除,但因面部神经受到明显刺激而放弃,最终接受了放射治疗(50.4 Gy,28 次)。在 1 年的随访中,患者报告主观听力损失得到缓解,听力评估结果为 PTA 34 dB,ST 30 dB,SD 88%。结论 虽然 CPA 内的分裂瘤放射治疗历来与听力损失有关,但与高剂量放射外科手术相比,分次立体定向放射治疗(FSRT)可改善临床疗效。鉴于这种治疗方式的有效性,以及与手术相比患者生活质量的改善,FSRT 可被视为面神经分裂瘤患者的初始治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
31
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信